Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-14
2010-06-29
Myers, Carla (Department: 1634)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S021800, C530S350000, C435S006120, C435S007100, C536S023500
Reexamination Certificate
active
07745389
ABSTRACT:
The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.
REFERENCES:
patent: 4883784 (1989-11-01), Kaneko
patent: 6248365 (2001-06-01), Romisch
patent: 7011952 (2006-03-01), Hageman et al.
patent: 7108982 (2006-09-01), Hageman
patent: 7312050 (2007-12-01), Hageman et al.
patent: 7344846 (2008-03-01), Hageman et al.
patent: 7351524 (2008-04-01), Hageman et al.
patent: 2002/0015957 (2002-02-01), Hageman et al.
patent: 2002/0102581 (2002-08-01), Hageman et al.
patent: 2006/0281120 (2006-12-01), Gorin
patent: 2007/0020647 (2007-01-01), Hageman et al.
patent: 2007/0037183 (2007-02-01), Edwards
patent: 2007/0059835 (2007-03-01), Chalberg
patent: 2008/0146501 (2008-06-01), Hageman et al.
patent: WO 2006/062716 (2006-06-01), None
patent: WO 2006/096561 (2006-09-01), None
patent: WO 2007/022590 (2007-05-01), None
Edelhauser et al. Investigative Ophthalmology & Visual Science. Nov. 2008, 49: 4712-4720.
Rudinger, J. Peptide Hormones. Edited by Parsons, University Park Press, Baltimore, 1976, p. 1-7.
Skolnick et al. Trends in Biotechnology. 2000. 18(1): 34-39.
Noris et al. Clinical and Experimental Immunology. 2008. 151: 199-209.
Schmidt et al. Clinical and Experimental Immunology. 2008. 151: 14-24.
Comer, G. et al., “Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration,”Drugs Aging, 2004; 21 (15): 967-992.
Conley, G. et al., “Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy,”Human Molecular Genetics, 2005, vol. 14, No. 14, pp. 1991-2002.
Gotoh, N. et al., “No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese,”Human Genetics, 2006, 120:139-143.
Goverdhan, S.V. et al., “Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis,”Atherosclerosis, May 2006, 188:213-214.
Halushka, M. et al., “Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis”,Nature Genetics, Jul. 1999, 22:239-247.
Hirschhorn, J. et al.,“A comprehensive review of genetic association studies,”Genetics in Medicine, Mar./Apr. 2002, vol. 4, No. 2, pp. 45-61.
Li, M. et al., “CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration,”Nature Genetics, Sep. 2006, vol. 38, No. 9, pp. 1049-1054.
Nicaud, V. et al., “Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction,”Journal of Molecular Medicine, 2007, 85:771-775.
Sanchez-Corral, P. et al., “Molecular basis for factor H and FHL-1 deficiency in an Italian Family,”Immunogenetics, 2000, 51:366-369.
Scholl, H.P.N. et al., “Y402H-Polymorphismus im Komplementfaktor H und altersabhängige Makuladegeneration (AMD)”,Ophthalmologe, 2005, 102:1029-1035 (English Abstract).
Schultz, D. et al., “Analysis of the ARMD1 locus: evidence that a mutation in Hemicentin-1 is associated with age-related macular degeneration in a large family,”Human Molecular Genetics, 2003, vol. 12, No. 24, pp. 3315-3323.
Sharma, A. et al., “Biologically active recombinant human complement factor H: synthesis and secretion by the baculovirus system,”Gene, 1994, 143:301-302.
Sorbena, L.A. et al., “Ranibizumab,”Drugs of the Future, 2003, 28(6): 541-545.
Souied, E. et al., “Y402H Complement factor H polymorphism associated with exudative age-related macular degeneration in the French population,”Molecular Vision, 2005, 11:1135-40.
Tedeschi-Blok, N. et al., “Population-Based Study of Early Age-Related Macular Degeneration, Role of the Complement Factor H Y402H Polymorphism in Bilateral but Not Unilateral Disease,”Ophthalmology, Jan. 2007, 114:99-103.
U.S. Appl. No. 60/653,078, filed Feb. 14, 2005, Hageman, et al.
U.S. Appl. No. 60/715,503, filed Sep. 9, 2005, Hageman, et al.
U.S. Appl. No. 60/717,861, filed Sep. 16, 2005, Hageman, et al.
U.S. Appl. No. 60/735,697, filed Nov. 9, 2005, Hageman, et al.
Ambati, J., et al., Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies, Surv Ophthalmol (2003) 48(3):257-293.
Anderson, D., et al., A role for local inflammation in the formation of drusen in the aging eye, Am J Ophthalmol (2002) 134:411-431.
Appel, G., et al., Membranoproliferative glomerulonephritis type II (Dense Deposit Disease): An update, J Am Soc Nephrol (2005) 16:1392-1403.
Ault, B., et al., Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism, J Biol Chem (1997) 272:25168-25175.
Caprioli, J., et al., Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease, Hum Mol Genet (2003) 12:3385-3395.
de Jong, P., Risk Profiles for Ageing Macular Disease, Ophthalmologia (2004) 218 Suppl 1:5-16.
Dragon-Durey, M., et al., Heterozygous and Homozygous Factor H Deficiencies Associated with Hemolytic Uremic Syndrome or Membranoproliferative Glomerulonephritis: Report and Genetic Analysis of 16 Cases, J Am Soc Nephrol (2004) 15:787-795.
Edwards, A., et al., Complement Factor H Polymorphism and Age-Related Macular Degeneration, Science (2005) 308:421-424.
Esparza-Gordillo, J., et al., Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32, Human Mol. Genetics (2005) 14:703-712.
Espinosa-Heidman, D., et al., Macrophage Depletion Diminishes Lesion Size and Severity in Experimental Choroidal Neovascularization, Invest. Ophthalmol. Vis. Sci. (2003) 44:3586-3592.
Fremeaux-Bacchi, V., et al., The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts, J. Med Genet. (2005) 42(11):852-586.
Hageman, G., et al., A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration, Proc Natl Acad Sci USA (2005) 102:7227-7232.
Hageman, G., et al., Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells, FASEB J. (1999) 13:477-484.
Hageman, G., et al., An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration, Prog Retin Eye Res (2001) 20:705-732.
Haines, J., et al., Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration, Science (2005) 308:419-421.
Holz, F., et al., Pathogenesis of Lesions in Late Age-related Macular Disease, Am J Ophthalmol (2004) 137(3):504-510.
Jansen, J., et al., In situ complement activation in porcine membranoproliferative glomerulonephritis type II, Kidney Int (1998) 53(2):331-349.
Klein, R., et al., Complement Factor H Polymorphism in Age-Related Macular Degeneration, Science (2005) 308:385-389.
Manuelian, T., et al., Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome, J Clin Invest (2003) 111:1181-1190.
Meri, S., et al., Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H, Biochem Biophys Res Commun (1994) 198:52-59.
Mullins, R., et al., Structure and composition of drusen associated with glomerulonephritis: Implications for the role of complement activation in drusen biogenesis, Eye (2001) 15:390-395.
Perez-Caballero, D., et al., Clustering of Misse
Myers Carla
Townsend and Towsend and Crew LLP
University of Iowa Research Foundation
LandOfFree
Methods for treatment of age-related macular degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of age-related macular degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of age-related macular degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242642